Literature DB >> 15913489

Is hypertension a prothrombotic state?

George I Varughese1, Gregory Y H Lip.   

Abstract

Hypertension is complicated by thrombosis-related events (such as myocardial infarction and stroke), and despite the high vascular pressures, these thrombotic occlusive events paradoxically occur more often than hemorrhagic episodes. The predisposition for thrombogenesis is increased in hypertension, which leads to changes in the platelets, endothelium, and matrix metalloproteinases and their inhibitors, as well as the coagulation and fibrinolytic pathways, which help promote the induction and the maintenance of this prothrombotic or hypercoagulable state. Other cardiovascular diseases, such as atrial fibrillation, congestive heart failure, and left ventricular hypertrophy, which may occur as a result of untreated hypertension, can also activate the prothrombotic state. These changes can, to a certain degree, be reversed by the treatment of hypertension, although the effects may be inconsistent. The evidence for antithrombotic therapy is less consistent, but in "high risk" hypertensive patients, antiplatelet therapy is useful.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15913489     DOI: 10.1007/s11906-005-0005-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  44 in total

1.  Inhibition of platelet aggregability by losartan in essential hypertension.

Authors:  P J Levy; C Yunis; J Owen; K B Brosnihan; R Smith; C M Ferrario
Journal:  Am J Cardiol       Date:  2000-12-01       Impact factor: 2.778

2.  Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression.

Authors:  Y Ding; N D Vaziri
Journal:  J Pharmacol Exp Ther       Date:  2000-02       Impact factor: 4.030

3.  Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy.

Authors:  P Erne; P Bolli; E Bürgisser; F R Bühler
Journal:  N Engl J Med       Date:  1984-04-26       Impact factor: 91.245

4.  Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy.

Authors:  C R Gibbs; A D Blann; R D Watson; G Y Lip
Journal:  Circulation       Date:  2001-04-03       Impact factor: 29.690

5.  Evidence of platelet activation in hypertension.

Authors:  A D Blann; G Y Lip; I F Islim; D G Beevers
Journal:  J Hum Hypertens       Date:  1997-09       Impact factor: 3.012

6.  Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure.

Authors:  B S P Chin; A D Blann; C R Gibbs; N A Y Chung; D G Conway; G Y H Lip
Journal:  Eur J Clin Invest       Date:  2003-11       Impact factor: 4.686

7.  Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation.

Authors:  Muzahir H Tayebjee; Sunil K Nadar; Robert J MacFadyen; Gregory Y H Lip
Journal:  Am J Hypertens       Date:  2004-09       Impact factor: 2.689

8.  Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation.

Authors:  F Marín; V Roldán; V E Climent; A Ibáñez; A García; P Marco; F Sogorb; G Y H Lip
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

Review 9.  Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle.

Authors:  T F Lüscher; Z Yang
Journal:  Drugs       Date:  1993       Impact factor: 9.546

10.  Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?

Authors:  Natali A Y Chung; Funmi Belgore; Foo Leong Li-Saw-Hee; Dwayne S G Conway; Andrew D Blann; Gregory Y H Lip
Journal:  Stroke       Date:  2002-09       Impact factor: 7.914

View more
  12 in total

1.  HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation.

Authors:  Kaku A Armah; Kathleen McGinnis; Jason Baker; Cynthia Gibert; Adeel A Butt; Kendall J Bryant; Matthew Goetz; Russell Tracy; Krisann K Oursler; David Rimland; Kristina Crothers; Maria Rodriguez-Barradas; Steve Crystal; Adam Gordon; Kevin Kraemer; Sheldon Brown; Mariana Gerschenson; David A Leaf; Steven G Deeks; Charles Rinaldo; Lewis H Kuller; Amy Justice; Matthew Freiberg
Journal:  Clin Infect Dis       Date:  2012-04-24       Impact factor: 9.079

2.  Brain injury after intracerebral hemorrhage in spontaneously hypertensive rats.

Authors:  Gang Wu; Xuhui Bao; Guohua Xi; Richard F Keep; B Gregory Thompson; Ya Hua
Journal:  J Neurosurg       Date:  2011-02-04       Impact factor: 5.115

3.  Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation.

Authors:  George I Varughese; Jeetesh V Patel; Joseph Tomson; Gregory Y H Lip
Journal:  Heart       Date:  2006-09-27       Impact factor: 5.994

4.  A clinical cardiology perspective of thrombophilias.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

Review 5.  Tissue factor, protease activated receptors and pathologic heart remodelling.

Authors:  Silvio Antoniak; Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Thromb Haemost       Date:  2014-08-07       Impact factor: 5.249

6.  Effects of serum homocysteine and adiponectin levels on platelet aggregation in untreated patients with essential hypertension.

Authors:  Hakan Ekmekçi; Ozlem Balci Ekmekçi; Serap Erdine; Hüseyin Sönmez; Yusup Ataev; Zeynep Oztürk; Ilknur Işler Bütün; Ciğdem Gürel; Mine Kucur; Nurver Turfaner; Turgut Ulutin; Sevim Purisa; Vural Ali Vural
Journal:  J Thromb Thrombolysis       Date:  2008-11-11       Impact factor: 2.300

7.  Relationship between mean platelet volume and morning blood pressure surge in newly diagnosed hypertensive patients.

Authors:  Hakan Uçar; Mustafa Gür; Mehmet Yavuz Gözükara; Ali Kıvrak; Zekeriya Kolcu; Selehattin Akyol; Onur Kaypaklı; Zafer Elbasan; Durmuş Yıldıray Şahin; Caner Türkoğlu; Taner Şeker; Murat Çaylı
Journal:  Anatol J Cardiol       Date:  2014-04-08       Impact factor: 1.596

8.  PPARγ ligands decrease hydrostatic pressure-induced platelet aggregation and proinflammatory activity.

Authors:  Fang Rao; Ren-Qiang Yang; Xiao-Shu Chen; Jin-Song Xu; Hui-Min Fu; Hai Su; Ling Wang
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

9.  The association between mean platelet volume and inflammation in geriatric patients with emergency hypertension.

Authors:  Mehmet Tahir Gokdemir; Gul Sahika Gokdemir; Mahmut Taş
Journal:  Turk J Emerg Med       Date:  2018-03-28

10.  Clinical Management of Hypertension, Inflammation and Thrombosis in Hospitalized COVID-19 Patients: Impact on Survival and Concerns.

Authors:  Patricia Martínez-Botía; Ángel Bernardo; Andrea Acebes-Huerta; Alberto Caro; Blanca Leoz; Daniel Martínez-Carballeira; Carmen Palomo-Antequera; Inmaculada Soto; Laura Gutiérrez
Journal:  J Clin Med       Date:  2021-03-04       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.